Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents
暂无分享,去创建一个
F. Zhan | Yingle Liu | Yu Chen | Qianyun Liu | Ke Xu | K. Lan | Yongzhong Jiang | Li Zhou | Huan Yan | Wenjing Zou | K. Cai | Chen Liu | Q. Xiong | Bing Hu | Junqiang Xu | Xianying Chen | Lianghui Dong | Fanghua Mei | Chengbao Ma | Fang Liu | Kun Cai
[1] T. Ndung’u,et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization , 2021, Nature.
[2] P. Maes,et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization , 2021, Nature.
[3] Fei Shao,et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.
[4] Qiang Liu,et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost , 2021, Emerging microbes & infections.
[5] O. Dyer. Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show , 2021, BMJ.
[6] Liyuan Liu,et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 , 2021, Nature.
[7] O. Tsang,et al. Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients , 2021, medRxiv.
[8] A. Telenti,et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift , 2021, Nature.
[9] J. Nie,et al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron , 2021, Emerging microbes & infections.
[10] E. Callaway. Omicron likely to weaken COVID vaccine protection , 2021, Nature.
[11] Xin He,et al. SARS-CoV-2 Omicron strain exhibits potent capabilities for immune evasion and viral entrance , 2021, Signal Transduction and Targeted Therapy.
[12] Y. Kawaoka,et al. Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation , 2021, Nature.
[13] E. Callaway. Heavily mutated Omicron variant puts scientists on alert , 2021, Nature.
[14] Suhua Zhou,et al. Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China , 2021, The Innovation.
[15] D. Wesemann,et al. Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant , 2021, bioRxiv.
[16] F. Zhan,et al. Antibody neutralization to SARS-CoV-2 and variants after one year in Wuhan , 2021, medRxiv.
[17] William T. Harvey,et al. SARS-CoV-2 variants, spike mutations and immune escape , 2021, Nature Reviews Microbiology.
[18] M. Bachmann,et al. Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China , 2020, Nature Communications.
[19] Vineet D. Menachery,et al. Spike mutation D614G alters SARS-CoV-2 fitness , 2020, Nature.
[20] J. Nie,et al. Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay , 2020, Nature Protocols.
[21] Bo Zhong,et al. RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak , 2020, Emerging microbes & infections.
[22] Dong Wei-quan,et al. A Discussion on the Project Management Practice of Fundamental Research Funds for the Central Universities , 2012 .